5. 罗氏公司

    • 2013年研发支出：100亿美元

    • 占收入的百分比：19%

    这家瑞士生物制药公司的研发支出金额在医疗保健行业处于首位。三年前，罗氏公司（Roche）曾在这份榜单中登顶。和那时相比，该公司目前为研发投入了更多的资金，而且绝大多数（几乎达到90%）都用在了药品研制领域，其余资金则投向了诊断产品研发。罗氏最大的业务是抗肿瘤药物，约占药品研发支出的一半。该公司用于治疗晚期癌症的靶向新药Kadcyla去年在美国和欧洲获得批文。罗氏称，该公司正在考虑将Kadcyla的部分平台（比如创造性地实现了化疗药物和抗体的偶联）用于今后的药物研发。

    5. Roche

    • R&D spending in 2013: $10 billion

    • As a percentage of revenue: 19%

    Leading the healthcare industry in R&D spending, the Swiss biopharmaceutical company spends more today than it did when it topped the Strategy& list three years ago. The company invests an overwhelming majority of its R&D budget —almost 90%—on pharmaceuticals, while the rest goes into diagnostics. Oncology, the largest part of Roche’s business, eats about half of its pharma R&D spending. One of the company’s latest drugs, a targeted medicine for advanced breast cancer called Kadcyla, was approved in the U.S. and E.U. last year. Roche says it is looking to leverage parts of the Kadcyla platform (for instance, the innovative way it links chemotherapeutic agents and antibodies) for future drugs.